Exelixis | EXEL - Operating Expenses


Exelixis reported $362.75M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bayer EUR 10.2B 523M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Exelixis USD 362.75M 21.35M Dec/2025
Genmab DKK 565M 38M Jun/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sanofi EUR 10.71B 1.32B Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Xencor USD 68.52M 8.26M Sep/2025